Publications

BibTex format

@article{Moccia:2020:10.1186/s12913-020-05664-x,
author = {Moccia, M and Loperto, I and Lanzillo, R and Capacchione, A and Carotenuto, A and Triassi, M and Morra, VB and Palladino, R},
doi = {10.1186/s12913-020-05664-x},
journal = {BMC Health Services Research},
pages = {1--8},
title = {Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)},
url = {http://dx.doi.org/10.1186/s12913-020-05664-x},
volume = {20},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundTo differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level.MethodsIn this population-based study, we included individuals with MS living in the Campania Region of Italy from 2015 to 2017, on treatment with intramuscular Interferon Beta-1a (Avonex® = 618), subcutaneous pegylated Interferon Beta-1a (Plegridy® = 259), subcutaneous Interferon Beta-1a (Rebif® = 1220), and subcutaneous Interferon Beta-1b (Betaferon® = 348; and Extavia® = 69). We recorded healthcare resource utilisation from administrative databases (hospital discharges, drug prescriptions, MS-related outpatients), and derived costs from the Regional formulary. We classified hospital admissions into MS-related and non-MS-related. Persistence (time to switch to other disease modifying treatments (DMTs)), and adherence (medication possession ratio (MPR) = medication supply obtained/medication supply expected during follow-up period) were calculated.ResultsPatients treated with Rebif® were younger, when compared with other Interferon Beta formulations (p < 0.01). The probability of switching to other DMTs was 60% higher for Betaferon®, 90% higher for Extavia®, and 110% higher for Plegridy®, when compared with Rebif® (p < 0.01). Plegridy® presented with 7% higher adherence (p < 0.01), and Betaferon® with 3% lower adherence (p = 0.03), when compared with Rebif®. The probability of MS-related hospital admissions was 40% higher in Avonex® (p = 0.03), 400% higher in Betaferon® (p < 0.01), and 60% higher in Plegridy® (p = 0.04), resulting into higher non-DMT-related costs, when compared with Re
AU  - Moccia,M
AU  - Loperto,I
AU  - Lanzillo,R
AU  - Capacchione,A
AU  - Carotenuto,A
AU  - Triassi,M
AU  - Morra,VB
AU  - Palladino,R
DO  - 10.1186/s12913-020-05664-x
EP  - 8
PY  - 2020///
SN  - 1472-6963
SP  - 1
TI  - Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
T2  - BMC Health Services Research
UR  - http://dx.doi.org/10.1186/s12913-020-05664-x
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000567074900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-020-05664-x#Abs1
UR  - http://hdl.handle.net/10044/1/85392
VL  - 20
ER  -

Download

DrRaffaelePalladino

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)